Somewhat Positive Media Coverage Somewhat Unlikely to Impact Vistagen Therapeutics (VTGN) Share Price
Press coverage about Vistagen Therapeutics (NASDAQ:VTGN) has been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Vistagen Therapeutics earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.8581026009644 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Separately, Chardan Capital cut their price objective on shares of Vistagen Therapeutics from $30.00 to $22.00 and set a “buy” rating on the stock in a report on Thursday, February 8th.
VTGN stock traded down $0.03 during mid-day trading on Wednesday, reaching $1.21. 121,530 shares of the company’s stock were exchanged, compared to its average volume of 950,042. Vistagen Therapeutics has a 12 month low of $0.69 and a 12 month high of $2.65. The firm has a market capitalization of $28.63, a PE ratio of -0.88 and a beta of -1.01.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-vistagen-therapeutics-vtgn-share-price/1952763.html.
Vistagen Therapeutics Company Profile
VistaGen Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA).
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.